{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T05:07:59Z","timestamp":1700284079696},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,2,25]],"date-time":"2003-02-25T00:00:00Z","timestamp":1046131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adenosine deaminase inhibitors have proven superior to alkylating agent\u2010based therapies in inducing clinical and hematologic remissions in treated and previously untreated chronic lymphocytic leukemia (CLL) patients, and they have become increasingly accepted as a standard for therapy. We report the case of a 66\u2010year\u2010old patient with a 7\u2010year history of CLL who had been previously treated with alkylating agents. Upon presentation with abdominal lymphadenopathy, a 5\u2010day course of the nucleoside analogue, fludarabine, was administered. Two days after completion, the patient developed acute tumor lysis syndrome (TLS) that induced renal failure with hyperkalemia and hyperuricemia. This resulted in critical, life\u2010threatening complications requiring hospitalization, aggressive hemodialysis and fluid replacement therapy. While only 5 other cases of TLS associated with fludarabine therapy have been reported since 1989, we recommend that adenosine deaminase inhibitor therapy be initiated with the addition of allopurinol, and that hydration with copious amounts of oral fluids during therapy be encouraged in order to help protect against the renal effects of potential TLS induced by these agents. Am. J. Hematol. 72:212\u2013215, 2003. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.10283","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T23:06:31Z","timestamp":1048028791000},"page":"212-215","source":"Crossref","is-referenced-by-count":21,"title":["Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): Case report and review of the literature"],"prefix":"10.1002","volume":"72","author":[{"given":"Kashif","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Clouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,2,25]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1961.tb00321.x"},{"key":"e_1_2_1_3_2","first-page":"457","article-title":"Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia","volume":"30","author":"Grever MR","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"issue":"5","key":"e_1_2_1_4_2","first-page":"49","article-title":"Fludarabine phosphate in the treatment of chronic lymphocytic leukemia","volume":"17","author":"Keating MJ","year":"1990","journal-title":"Semin Oncol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.44"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609093445"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009057630"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010604"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008273131598"},{"issue":"5","key":"e_1_2_1_10_2","first-page":"2","article-title":"Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies","volume":"20","author":"Plunkett W","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_1_11_2","first-page":"1005","article-title":"Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies","volume":"53","author":"Adkins JC","year":"1997","journal-title":"Drugs"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1165"},{"issue":"3","key":"e_1_2_1_13_2","first-page":"14","article-title":"Therapy for previously untreated chronic lymphocytic leukemia: a re\u2010evaluation","volume":"35","author":"Cheson BD","year":"1998","journal-title":"Semin Hematol"},{"key":"e_1_2_1_14_2","first-page":"275","volume-title":"Chronic lymphoid leukemias","author":"Thomas DA","year":"2001"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211053271921"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.70.827.651"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01939.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1994.tb01473.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90358-K"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2313"},{"key":"e_1_2_1_21_2","first-page":"273","article-title":"Tumor lysis syndrome","volume":"13","author":"Arrambide K","year":"1993","journal-title":"Semin Nephrol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006341717398"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209051009"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.1999.35.2.527964"},{"key":"e_1_2_1_25_2","first-page":"488","article-title":"Acute tumour lysis syndrome","volume":"49","author":"Chasty RC","year":"1993","journal-title":"Br J Hosp Med"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00860751"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.10.3429.3429"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)00410-7"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404143301517"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.10283","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.10283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:25:30Z","timestamp":1700277930000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.10283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,25]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1002\/ajh.10283"],"URL":"https:\/\/doi.org\/10.1002\/ajh.10283","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,25]]}}}